On November 19, 2012, VIVUS, Inc., or the Company, initiated the QsymiaTM Get
Started! Free Trial Offer Program. The Company is offering eligible patients a
Free Trial Offer on a valid prescription for up to a 14 capsule quantity of the
Qsymia Starting Dose, 3.75 mg/23 mg (phentermine and topiramate
extended-release). Eligible patients are able to receive up to 14 capsules of
Qsymia Starting Dose free, including standard shipping and handling charges.

For a patient to qualify for the Get Started! Free Trial Offer Program, they
must meet the following eligibility criteria: reside in one of the 50 states,
Puerto Rico, Virgin Islands, or Guam and be 18 years or older. This offer is
not insurance and is not valid for prescriptions purchased under Medicaid,
Medicare or similar federal or state programs or for patients who are Medicare
eligible and enrolled in an employer-sponsored group waiver health plan or
government-subsidized prescription drug benefit program for retirees. This
offer is not valid where prohibited by law, taxed or restricted, and this offer
is limited to one per patient for the duration of the program.

This program is only available through CVS mail order and Walgreens mail order
pharmacies that are part of the Qsymia Home Delivery Network. Healthcare
providers and patients will be notified of this program through several
communication routes, including being prominently displayed on Qsymia.com.

By filing this information, the Company makes no admission as to the materiality
of any information in this report. The information contained in this report is
intended to be considered in the context of the Company's filings with the
Securities and Exchange Commission and other public announcements that the
Company makes, by press release or otherwise, from time to time. The Company
undertakes no duty or obligation to publicly update or revise the information
contained in this report, although it may do so from time to time as its
management believes is appropriate. Any such updating may be made through the
filing of other reports or documents with the Securities and Exchange
Commission, through press releases or through other public disclosure.

The information in this Form 8-K shall not be deemed "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), or otherwise subject to the liabilities of that Section, or incorporated
by reference into any of the Registrant's filings under the Securities Act of
1933, as amended, or the Exchange Act, except as shall be expressly set forth by
specific reference in any such filing.